Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;14(2):193-202.

Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole

Kevin Watt  1 , Paolo Manzoni, Michael Cohen-Wolkowiez, Stefano Rizzollo, Elena Boano, Evelyne Jacqz-Aigrain, Daniel K Benjamin
Affiliations
Review

Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole

Kevin Watt et al. Curr Drug Metab. 2013 Feb.

Abstract

Invasive fungal infections in infants admitted to the neonatal intensive care unit are common and often fatal. The mainstay of therapy against invasive fungal infections is antifungal agents. Over the last two decades, the development and approval of these drugs evolved tremendously, and the azole class emerged as important agents in the treatment and prevention of invasive fungal infections. Among the azoles, fluconazole has been used extensively due to its favorable pharmacokinetics, excellent activity against Candida spp, and safety profile. This drug has been well studied in children, but data for its use in infants are largely limited to Candida prophylaxis studies. Voriconazole, a second generation triazole, has excellent activity against Candida and Aspergillus spp. However, data on its use in neonates are extremely limited. Posaconazole and ravuconazole are the newest agents of the triazole family. The antimicrobial spectrum of posaconazole is similar to voriconazole, but with additional activity against zygomycetes. Experience with posaconazole in children is very limited, and there are no reports of its use in infants. Ravuconazole is not approved for use by the FDA, but studies in animals and humans show that it is often fungicidal and has favorable pharmacokinetics. In conclusion, the management of invasive fungal infections has progressed greatly over the last two decades with the azole antifungals playing a significant role. Related to this class, future research is needed in order to better assess dosing, safety, schedules and areas of use of these agents in infants admitted to the neonatal intensive care unit.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of ECMO circuit.
See this image and copyright information in PMC

References

    1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–291. - PubMed
    1. Benjamin DK, Jr, Stoll BJ. Infection in late preterm infants. Clin. Perinatol. 2006;33(4):871–882. - PubMed
    1. Benjamin DK, Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92. - PubMed
    1. Makhoul IR, Bental Y, Weisbrod M, Sujov P, Lusky A, Reichman B Israel Neonatal Network. Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J Hosp. Infect. 2007;65(3):237–243. - PubMed
    1. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch. Dis. Child. Fetal Neonatal Ed. 2006;91(3):F188–F192. - PMC - PubMed

Publication types